Carranza FH, Iglesias SG, De Mingo Domínguez ML, et al. - In this study, the long‐term impacts of TSH suppression therapy with Levothyroxine on the trabecular bone score (TBS) and bone mineral density (BMD) were tested in females with differentiated thyroid cancer (DTC) after thyroidectomy. According to the degree of TSH suppression, about 145 women with resected DTC and receiving long‐term TSH therapy, were stratified (the Mean duration of follow‐up was 12.3 ± 6.1 years). Dual‐energy x‐ray absorptiometry and TBS iNsight (Med‐Imaps) were applied to evaluate BMD and TBS, at baseline (1‐3 months after surgery) and at the final study visit. The study reported the deterioration of trabecular structure in patients with DTC and TSH suppression therapy below 0.1 µU/mL and after 5‐10 years of follow‐up. There were no significant changes in BMD according to TSH levels. A trabecular Bone Score was found to be beneficial technique for distinguishing thyroid cancer patients with the risk of bone deterioration.